Nektar Therapeutics Shareholder Claims Notification
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 26 2026
0mins
Should l Buy NKTR?
Source: PRnewswire
- Shareholder Claim Opportunity: Investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, may be entitled to recover losses, particularly after the company's stock fell 7.77% due to poor trial results.
- Trial Result Impact: On December 16, 2025, Nektar's shares dropped by $4.14 to close at $49.16 after it was revealed that four ineligible patients were enrolled in the REZOLVE-AA study, severely impacting investor confidence.
- Management Concealment Issues: The lawsuit alleges that management repeatedly claimed rigorous trial standards over ten months while concealing violations of those standards, leading to a decline in investor trust in the company.
- Claim Deadline: Investors must submit claims by May 5, 2026, raising questions about the fairness and efficiency of the market due to the failure to timely disclose material developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 91.260
Low
102.00
Averages
123.43
High
165.00
Current: 91.260
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nektar Therapeutics Closes $373.8 Million Public Offering
- Offering Amount: Nektar Therapeutics successfully closed a public offering of $373.8 million, selling 4,062,500 shares of common stock, indicating strong market confidence in its immunology therapies.
- Share Price Performance: The offering price of $92.00 per share reflects optimistic investor expectations regarding Nektar's future product pipeline, potentially providing substantial funding for ongoing research and development.
- Underwriter Participation: Jefferies, TD Cowen, and Piper Sandler acted as joint bookrunning managers for the offering, enhancing market recognition of Nektar while laying a foundation for future financing activities.
- Registration Statement Validity: The offering was conducted under a shelf registration statement filed on November 12, 2025, ensuring compliance and transparency, which helps to build investor trust.
See More
Nektar Therapeutics Class Action Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by May 5, 2026, to participate in the class action against Nektar Therapeutics, which involves those who purchased securities between February 26 and December 15, 2025, highlighting the urgency of legal action.
- Trial Result Failure: On December 16, 2025, Nektar announced that its REZOLVE-AA trial results did not achieve statistical significance, causing a 7.8% drop in stock price to $49.16 per share, directly impacting investor confidence and the company's market performance.
- False Statement Allegations: The lawsuit alleges that Nektar failed to disclose enrollment issues in the REZOLVE-AA trial, which likely had a significant negative impact on the trial's results, reflecting misleading statements about the company's business prospects.
- Investor Losses: Due to the negative impact of the trial results, investors face losses, and the lawsuit aims to recover economic damages caused by the company's failure to disclose critical information, emphasizing the importance of transparency and compliance.
See More
Class Action Filed Against Nektar Therapeutics for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Nektar Therapeutics, seeking damages for investors who purchased securities between February 26, 2025, and December 25, 2025, highlighting serious concerns over the company's compliance and operational transparency.
- Detailed Allegations: The complaint alleges that Nektar failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, which could significantly negatively impact the trial's results, indicating severe management deficiencies in critical R&D projects that undermine investor confidence.
- Investor Action Call: Affected investors are urged to apply to be lead plaintiffs by May 5, 2026, reflecting the urgency of the legal proceedings and the uncertainty surrounding the company's future prospects.
- Legal Fee Arrangement: Bronstein, Gewirtz & Grossman, LLC states they will represent investors on a contingency fee basis, meaning they will only charge fees if successful in recovering damages, thus reducing financial risk for investors and encouraging broader participation in the lawsuit.
See More
Nektar Therapeutics Upsizes Public Offering to $325 Million
- Upsized Offering: Nektar Therapeutics has increased its public offering from the initially planned $250 million to $325 million, pricing 3.53 million shares at $92 each, which is expected to yield approximately $325 million, indicating strong market support for its financing needs.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated for general corporate purposes, including research and development, clinical development (notably Phase 3 trials for Rezpegaldesleukin in atopic dermatitis and alopecia areata), and manufacturing costs, aimed at accelerating the advancement of its drug candidates and enhancing future market competitiveness.
- Underwriter Selection: Nektar has appointed Jefferies, TD Cowen, and Piper Sandler as joint bookrunning managers for this offering, reflecting the company's trust and collaborative relationships in the capital markets, which further enhances the professionalism and market recognition of its financing efforts.
- Stock Performance Volatility: NKTR's stock has traded between $7.99 and $109 over the past year, and despite closing down 2.18% at $98.16 on Tuesday, it rose 1.18% to $99.32 in pre-market trading, indicating a positive market reaction to the offering news.
See More
Nektar Therapeutics Prices Upsized $325M Public Offering
- Upsized Offering: Nektar Therapeutics has announced an increase in its public offering from an initially proposed $250 million to $325 million, indicating strong market demand and expected significant funding support for the company.
- Offering Details: The company is selling 3.53 million shares at a price of $92.00 per share, with gross proceeds expected to be around $325 million before fees and expenses, which will be allocated for general corporate purposes including R&D and clinical development.
- Underwriter Option: Nektar has granted underwriters a 30-day option to purchase an additional 529,891 shares at the same price, further enhancing investor interest in the stock.
- Use of Proceeds: The net proceeds are planned to be used for research and manufacturing costs, including Phase 3 trials for rezpegaldesleukin, which will help advance its drug candidates and strengthen future market competitiveness.
See More
Nektar Therapeutics Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action.
- Fee Arrangement: Investors participating in the Nektar class action will not incur any out-of-pocket costs, as the law firm will operate on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that the defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated trial integrity and resulting in investor losses once the true details were disclosed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its strong capabilities in this field.
See More
Nektar Therapeutics Closes $373.8 Million Public Offering
- Offering Amount: Nektar Therapeutics successfully closed a public offering of $373.8 million, selling 4,062,500 shares of common stock, indicating strong market confidence in its immunology therapies.
- Share Price Performance: The offering price of $92.00 per share reflects optimistic investor expectations regarding Nektar's future product pipeline, potentially providing substantial funding for ongoing research and development.
- Underwriter Participation: Jefferies, TD Cowen, and Piper Sandler acted as joint bookrunning managers for the offering, enhancing market recognition of Nektar while laying a foundation for future financing activities.
- Registration Statement Validity: The offering was conducted under a shelf registration statement filed on November 12, 2025, ensuring compliance and transparency, which helps to build investor trust.
See More
Nektar Therapeutics Class Action Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by May 5, 2026, to participate in the class action against Nektar Therapeutics, which involves those who purchased securities between February 26 and December 15, 2025, highlighting the urgency of legal action.
- Trial Result Failure: On December 16, 2025, Nektar announced that its REZOLVE-AA trial results did not achieve statistical significance, causing a 7.8% drop in stock price to $49.16 per share, directly impacting investor confidence and the company's market performance.
- False Statement Allegations: The lawsuit alleges that Nektar failed to disclose enrollment issues in the REZOLVE-AA trial, which likely had a significant negative impact on the trial's results, reflecting misleading statements about the company's business prospects.
- Investor Losses: Due to the negative impact of the trial results, investors face losses, and the lawsuit aims to recover economic damages caused by the company's failure to disclose critical information, emphasizing the importance of transparency and compliance.
See More
Class Action Filed Against Nektar Therapeutics for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Nektar Therapeutics, seeking damages for investors who purchased securities between February 26, 2025, and December 25, 2025, highlighting serious concerns over the company's compliance and operational transparency.
- Detailed Allegations: The complaint alleges that Nektar failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, which could significantly negatively impact the trial's results, indicating severe management deficiencies in critical R&D projects that undermine investor confidence.
- Investor Action Call: Affected investors are urged to apply to be lead plaintiffs by May 5, 2026, reflecting the urgency of the legal proceedings and the uncertainty surrounding the company's future prospects.
- Legal Fee Arrangement: Bronstein, Gewirtz & Grossman, LLC states they will represent investors on a contingency fee basis, meaning they will only charge fees if successful in recovering damages, thus reducing financial risk for investors and encouraging broader participation in the lawsuit.
See More
Nektar Therapeutics Upsizes Public Offering to $325 Million
- Upsized Offering: Nektar Therapeutics has increased its public offering from the initially planned $250 million to $325 million, pricing 3.53 million shares at $92 each, which is expected to yield approximately $325 million, indicating strong market support for its financing needs.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated for general corporate purposes, including research and development, clinical development (notably Phase 3 trials for Rezpegaldesleukin in atopic dermatitis and alopecia areata), and manufacturing costs, aimed at accelerating the advancement of its drug candidates and enhancing future market competitiveness.
- Underwriter Selection: Nektar has appointed Jefferies, TD Cowen, and Piper Sandler as joint bookrunning managers for this offering, reflecting the company's trust and collaborative relationships in the capital markets, which further enhances the professionalism and market recognition of its financing efforts.
- Stock Performance Volatility: NKTR's stock has traded between $7.99 and $109 over the past year, and despite closing down 2.18% at $98.16 on Tuesday, it rose 1.18% to $99.32 in pre-market trading, indicating a positive market reaction to the offering news.
See More
Nektar Therapeutics Prices Upsized $325M Public Offering
- Upsized Offering: Nektar Therapeutics has announced an increase in its public offering from an initially proposed $250 million to $325 million, indicating strong market demand and expected significant funding support for the company.
- Offering Details: The company is selling 3.53 million shares at a price of $92.00 per share, with gross proceeds expected to be around $325 million before fees and expenses, which will be allocated for general corporate purposes including R&D and clinical development.
- Underwriter Option: Nektar has granted underwriters a 30-day option to purchase an additional 529,891 shares at the same price, further enhancing investor interest in the stock.
- Use of Proceeds: The net proceeds are planned to be used for research and manufacturing costs, including Phase 3 trials for rezpegaldesleukin, which will help advance its drug candidates and strengthen future market competitiveness.
See More
Nektar Therapeutics Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action.
- Fee Arrangement: Investors participating in the Nektar class action will not incur any out-of-pocket costs, as the law firm will operate on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that the defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated trial integrity and resulting in investor losses once the true details were disclosed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its strong capabilities in this field.
See More
